Get the Stockscreener App
0.7395
4.15%
0.0295
After Hours:
.72
-0.0195
-2.64%
Hoth Therapeutics Inc stock is traded at $0.7395, with a volume of 171.92K.
It is up +4.15% in the last 24 hours and up +27.72% over the past month.
Hoth Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing new-generation therapies for unmet medical needs. It is focused on developing a topical formulation for treating side effects from drugs used for the treatment of cancer (HT-001); a treatment for mast-cell derived cancers and anaphylaxis (HT-KIT); and a treatment and/or prevention for Alzheimer's or other neuroinflammatory diseases (HT-ALZ). The company also has assets being developed for atopic dermatitis (also known as eczema) (BioLexa); a treatment for asthma and allergies using inhalational administration (HT-004); and an obesity treatment, and obesity-related diseases and conditions (HT-VA). Its current assets are focused in treating cancer, skin toxicities, Alzheimer's, and weight loss.
See More
Previous Close:
$0.71
Open:
$0.7001
24h Volume:
171.92K
Relative Volume:
0.08
Market Cap:
$14.14M
Revenue:
-
Net Income/Loss:
$-12.47M
P/E Ratio:
-0.8117
EPS:
-0.9111
Net Cash Flow:
$-10.10M
1W Performance:
+3.50%
1M Performance:
+27.72%
6M Performance:
-42.23%
1Y Performance:
-19.88%
1-Day Range:
$0.69
$0.7465
1-Week Range:
$0.683
$0.7587
52-Week Range:
$0.4894
$2.115
Hoth Therapeutics Inc Stock (HOTH) Company Profile
Name
Hoth Therapeutics Inc
Sector
Industry
Phone
(646)756-2997
Address
1177 AVENUE OF THE AMERICAS, NEW YORK, NY
Compare HOTH vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
HOTH
Hoth Therapeutics Inc
|
0.7395 | 13.58M | 0 | -12.47M | -10.10M | -0.9111 |
VRTX
Vertex Pharmaceuticals Inc
|
427.65 | 107.87B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
721.05 | 73.63B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
807.55 | 49.42B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
303.00 | 40.20B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
313.32 | 33.06B | 5.36B | 287.73M | 924.18M | 2.5229 |
Hoth Therapeutics Inc Stock (HOTH) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-15-19 | Initiated | The Benchmark Company | Speculative Buy |
Hoth Therapeutics Inc Stock (HOTH) Latest News
Hoth Therapeutics secures European authorization in Spain - marketscreener.com
Hoth Therapeutics secures Spain approval for phase 2a trial - Investing.com
Hoth Therapeutics Secures European Authorization in Spain for HT-001 Phase 2a Trial as Interim Data Show Strong Efficacy in Cancer Patients - The AI Journal
Cancer patients stayed on treatment as Hoth trial eased rash - Stock Titan
Hoth Therapeutics Receives Nasdaq Delisting Notice for Non-Compliance With Minimum Bid Price Rule - Minichart
Hoth Therapeutics Receives Nasdaq Minimum Bid Price Deficiency Notice - TipRanks
HOTH Should I Buy - Intellectia AI
Hoth Therapeutics Disclosed Failure to Satisfy a Continued Listing Rule or Standard - TradingView
Hoth Therapeutics (HOTH) faces Nasdaq $1 bid-price deficiency and delisting risk - Stock Titan
Why is HOTH stock up 70% after-hours today? - MSN
Exclusive: Hoth Therapeutics targets faster drug discovery with new AI platform - MSN
HOTH Technical Analysis | Trend, Signals & Chart Patterns | HOTH THERAPEUTICS INC (NASDAQ:HOTH) - ChartMill
HOTH Hoth Therapeutics Inc. posts wider than expected Q4 2025 loss even as shares climb nearly 8 percent in today's trading.Decline Risk - Cổng thông tin điện tử tỉnh Tây Ninh
Hoth Therapeutics, Inc.Common Stock (NQ: HOTH - The Chronicle-Journal
Hoth Therapeutics Is A High-Risk Biotech Betting On Trial Milestones - Finimize
Hoth Therapeutics (HOTH) Stock Volume Volatility (Bearish Momentum) 2026-04-18Trading Community - Cổng thông tin điện tử Tỉnh Sơn La
12 Health Care Stocks Moving In Friday's Pre-Market Session - Benzinga
Hoth Therapeutics Files 8-K with SEC Detailing Legal Opinion for NASDAQ-Listed Common Stock (HOTH) - Minichart
Hoth Therapeutics Resumes At-the-Market Equity Offering Program - TipRanks
Hoth Therapeutics to resume at-the-market offering with new prospectus filing - Investing.com
Hoth Therapeutics (NASDAQ: HOTH) to restart at-the-market stock program - Stock Titan
Hoth Therapeutics (NASDAQ: HOTH) files ATM prospectus to raise up to $1.56M - Stock Titan
Hoth Therapeutics Reports Positive HT VA Study Data Highlighting GDNF Driven Metabolic Reprogramming In Fatty Liver Disease - BioPharma APAC
12 Health Care Stocks Moving In Tuesday's After-Market Session - Benzinga
Emerging Now: ANY, GPRO, HOTH, SNAL Shift Strategic Focus in 2026 - openPR.com
12 Health Care Stocks Moving In Tuesday's Intraday Session - Benzinga
Move Over Novo NordiskThis Small Company Study Flags Edge In Fatty Liver Drug - Benzinga
Positive Results for Hoth Therapeutics (HOTH) in Liver Disease S - GuruFocus
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
Hoth reports preclinical data on GDNF for fatty liver disease By Investing.com - Investing.com South Africa
Hoth Therapeutics (HOTH) Reports Positive HT-VA CRADA Data: GDNF Reprograms Liver Fat Metabolism, Shuts Down Fat-Creation Gene and Activates Fat-Burning Pathways, Outperforming Semaglutide - Eastern Progress
Trending Stocks Today | Perfect Moment Surges 88.88% Pre-Market - Moomoo
Hoth Therapeutics Reports Positive GDNF Data for Fatty Liver Disease - National Today
In a fatty liver study, Hoth says GDNF beat semaglutide on key genes - Stock Titan
Why Is HOTH Stock Up 70% After-Hours Today? - Stocktwits
Hoth Therapeutics (Hoth) Reports Positive Ht-Va Crada Data Gdnf Reprograms Liver Fat Metabolism, Shuts Down Fat-Creation Gene And Activates Fat-Burning Pathways, Outperforming Semaglutide - TradingView — Track All Markets
Hoth Therapeutics announces issuance of Chinese patent for cancer cell-targeting technology - Select Science
HOTH.O Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
HOTH Q4 2025 Earnings: Hoth Therapeutics misses EPS estimates with zero revenueExpert Stock Picks - Cổng thông tin điện tử tỉnh Tây Ninh
Aug Update: Is Hoth Therapeutics Inc benefiting from innovation trends2026 Decliners & High Accuracy Investment Entry Signals - baoquankhu1.vn
HOTH.O Technical Analysis & Stock Price Forecast - Intellectia AI
Trend Report: Is Hoth Therapeutics Inc stock trending bullish2026 Institutional Moves & High Win Rate Trade Tips - baoquankhu1.vn
HOTH.O PE Ratio & Valuation, Is HOTH.O Overvalued - Intellectia AI
HOTH.O Forecast — Price Prediction for 2026. Should I Buy HOTH.O? - Intellectia AI
Hoth Therapeutics Inc Stock (HOTH) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.77%
0.25%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):